The purpose of the study was to evaluate whether testosterone replacement therapy improves muscle mechanical and physical function in addition to increasing lean leg mass and total lean body mass in aging men with type 2 diabetes and lowered bio-available testosterone (BioT) levels. Thirty-nine men aged 50-70 years with type 2 diabetes and BioT levels <7.3 nmol/L were included from an academic tertiary-care medical center. Patients were randomized to testosterone gel (testosterone replacement therapy, n = 20) or placebo (n = 19) for 24 weeks, applying a double-blinded design. Muscle mechanical function was assessed by Nottingham Leg Rig (leg extension power) and isokinetic dynamometry (knee extensor maximal isometric contraction, rate of force development (RFD100), maximal dynamic contraction (Dyn180)). Physical function was assessed by gait speed. Body composition was assessed by whole body dual-energy X-ray absorptiometry (total lean body mass, lean leg mass, total fat mass, leg fat mass). Levels of total testosterone (TotalT), BioT, free testosterone (FreeT), and sex hormone-binding globulin were measured from fasting blood samples. Coefficients (b) represent the placebo-controlled mean effect of intervention. Maximal isometric contraction (b = 18.4 Nm, p = 0.039), RFD100 (b = 195.0 Nm/s, p = 0.017) and Dyn180 (b = 10.2 Nm, p = 0.019) increased during testosterone replacement therapy compared with placebo. No changes were observed in leg power or gait speed. Total lean body mass (b = 1.9 kg, p = 0.001) and lean leg mass (b = 0.5 kg, p < 0.001) increased, while total fat mass (b = À1.3 kg, p = 0.009) and leg fat mass (b = À0.7 kg, p = 0.025) decreased during testosterone replacement therapy compared with placebo. Total T (b = 14.5 nmol/L, p = 0.056), BioT (b = 7.6 nmol/L, p = 0.046), and FreeT (b = 0.32 nmol/L, p = 0.046) increased during testosterone replacement therapy compared with placebo, while sex hormone-binding globulin (n = À2 nmol/L, p = 0.030) decreased. Knee extensor muscle mechanical function was preserved, and body composition improved substantially during testosterone replacement therapy for 24 weeks compared with placebo, whereas physical function (gait speed) was unchanged in aging men with type 2 diabetes and lowered BioT levels.
INTRODUCTION
A well-known trait of aging is the progressive loss of muscle mass, muscle mechanical function, and physical function (i.e., sarcopenia), eventually increasing the risk of adverse health outcomes (Cruz-Jentoft et al., 2010; Frost et al., 2015) . These agerelated negative effects has been shown to be much more pronounced in type 2 diabetes mellitus (T2D) as evidenced by cross-sectional studies reporting lower muscle mass, muscle mechanical function (strength and power), and physical function (gait speed) in aging men with T2D compared to agematched men without T2D (Volpato et al., 2012; Kalyani et al., 2013) . Moreover, a 3-year longitudinal study reported that aging individuals with T2D experienced a~50% more rapid decline of knee extensor muscle strength compared to age-matched individuals without T2D (corresponding to À4.5 vs. À3.0% per year, respectively) (Park et al., 2007) .
In part, the loss of muscle mass, muscle mechanical function, and physical function with advanced age are explained by a concomitant decrease in concentrations of bio-available (BioT) and free testosterone (FreeT) (Isidori et al., 2005; Srinivas-Shankar et al., 2010) , along with an increase in concentration of sex hormone-binding globulin (SHBG) leaving total testosterone (TotalT) unaffected (Frost et al., 2013) . The age-associated decreases in BioT and FreeT appear to become accelerated in T2D, with up to 58% of aging men with T2D having lowered BioT/FreeT levels (Grossmann et al., 2008; Dhindsa et al., 2010) . Without any treatment, aging men with T2D and lowered BioT/ FreeT levels may altogether have an elevated risk of experiencing loss of muscle mass, impairments in muscle mechanical function (e.g., muscle strength and power), and limitations in physical function (e.g., gait speed).
The use of testosterone replacement therapy (TRT) is a contentious issue in aging men, mainly as there are no clear organic causation of lowered testosterone levels (Huhtaniemi, 2014) along with uncertainties in whom to treat (Araujo et al., 2007; Wu et al., 2010) . TRT has nevertheless been shown effective in producing muscle hypertrophy (Srinivas-Shankar et al., 2010) and reducing fat mass (Grossmann et al., 2008) , and despite some minor inconsistencies, these adaptations have subsequently been shown to translate into improvements in muscle mechanical function and physical function in healthy aging men (Isidori et al., 2005; Storer et al., 2008 Storer et al., , 2016 Bhasin et al., 2012; Hildreth et al., 2013) .
On the basis of the above mentioned, it is plausible that aging men with T2D and lowered BioT levels would benefit from TRT by experiencing improvements in muscle mechanical function and physical function in addition to increments in muscle mass. To the best of our knowledge, this has not previously been examined.
MATERIALS AND METHODS
This study was a 24-week, randomized, double-blinded and placebo-controlled trial conducted at Odense University Hospital and the Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, from April 2012 to November 2013. The study was approved by the local ethics committee and the Danish Health and Medicines Authority, and all patients provided written consent. While the original trial was declared in ClinicalTrials.gov (identifier: NCT01560546), the present per-protocol study comprises additional exploratory analysis that was not pre-specified as an outcome.
Study design
The design of the trial has been reported in detail elsewhere (Magnussen et al., 2016) . Briefly, Caucasian men aged 50-70 years, BioT levels <7.3 nmol/L (Nielsen et al., 2007) , a diagnosis of T2D and stable treatment with metformin (only anti-diabetic drug permitted) at least three months prior to inclusion were eligible for inclusion. No change in anti-diabetic medication dose was allowed. The dosages of metformin were equally distributed between the two groups, as was the use of concomitant medication with 69% (27/39), 85% (33/39), 33% (13/39), 8% (3/39), and 8% (3/39) of patients taking antihypertensive drugs, cholesterol-lowering drugs, antithrombotic drugs, inhalation steroids, and antidepressants, respectively. Patients were recreationally physically active at baseline and instructed to maintain their levels of activity throughout the entire study.
Patients were randomly assigned to 5 g gel daily containing placebo (n = 21) or 50 mg testosterone, Testim â (TRT, n = 22).
Testosterone levels were evaluated after 3 weeks of treatment by medical doctors not blinded to group allocation, and the dose was increased to 10 g gel daily if the BioT level was <7.3 nmol/L. Hence, safety monitoring was externally handled to ensure continued blinding. Compliance was self-reported at each visit. Trial investigators and patients were blinded to the intervention allocation. Patients were examined before and after 24 weeks of treatment on two consecutive days, comprising medical examination, physical and muscle testing, dual-energy X-ray absorptiometry (DXA) scan, questionnaires on the first day, and fasting blood samples on the second day. Patients were told to stop gel therapy 24 h before blood sampling at week 3 and the second day of the final visit. The sample size of the original study (Magnussen et al., 2016) was determined by the anticipated effect of TRT on TLBM (Isidori et al., 2005) , resulting in 20 patients in each group. In the present explorative study, the primary outcome was isometric muscle strength (MVC), and the secondary outcomes included additional measures of muscle mechanical function (explosive strength, dynamic strength, and power), physical function (gait speed), lean leg mass, TLBM, TFM, and leg fat mass. Physical activity was assessed by accelerometry and considered as an explanatory outcome measure.
Muscle mechanical function
Knee extensor muscle mechanical function was assessed by experienced sports physiologists using the KinCom isokinetic dynamometer (KinCom 500H, Chattecx, Chattanooga, TN, USA) (Hvid et al., 2014) . Following several warm-up trials, patients performed five maximal voluntary dynamic contractions at 180°/s (dynamic strength, Dyn180) in a range of 90°to 20°and three maximal voluntary isometric contractions (isometric strength, MVC) at a 70°knee joint angle, where 0°equals full extension (Hvid et al., 2014) . Patients were instructed to contract as fast and forcefully as possible and maintain maximal force exertion for 2-3 s during the MVCs. Explosive muscle strength was calculated as the contractile rate of force development (Dforce/Dtime) in the time interval between 0 and 100 ms relative to the onset of contraction (explosive strength, RFD100). One-minute rest periods were given between each trial. All trials were gravity corrected and normalized to moment arm, and with trials having visible initial countermovement being discarded. The trial with the highest force was selected from the dynamic and isometric knee extensor muscle strength (from which RFD100 was calculated). MVC, Dyn180, and RFD100 values from the right and left leg were averaged and presented as absolute values (Nm and Nm/s, respectively). Similar individual test settings were applied throughout the study.
Leg extensor muscle power (=force*velocity) was assessed by experienced sports physiologists using the Nottingham Leg Rig (Nottingham, UK) (Caserotti et al., 2008) . Patients were seated in the power-rig chair in a 20°knee joint angle at full extension and pushed away the footplate connected to a flywheel as hard and fast as possible. A minimum of 5 trials were performed for each leg with visual feedback on a screen after each trial. The trial with the highest power was selected, averaged for the right and left leg, and presented as absolute values (W).
In a group of healthy individuals of comparable age range (Hvid et al., 2014) as in the present study, repeated measurements CV for MVC, Dyn180, RFD100, and power corresponded to 1.4, 3.3, 11.2, and 2.0%, respectively.
Gait speed (physical function)
Normal and maximal walking speed were assessed twice over a 10-m course using a stopwatch. The fastest trial was selected for each walking speed (test condition) and presented in absolute values (m/s).
Accelerometry (physical activity)
The accelerometer (ActiGraph GT3X+) was worn for seven consecutive days before treatment and during the last week of the intervention period to obtain an objective measure of physical activity. The patients were instructed to wear the device over the hip for all waking hours except when showering or swimming. Data were analyzed using the software program Propero (University of Southern Denmark, developed by Jan Brønd). Following sampling, data were analyzed and re-calculated into counts per minute (CPM). Non-wear time defined as periods of 60 min or more of consecutive zero counts were excluded from the analyses. To ensure that the data were representative of normal physical activity levels, patients had to accumulate at least 10 h of activity per day for at least 4 of the 7 days. Time spent at different physical activity intensities levels was assessed in minutes per day (min/d), comprising 0-99 CPM (sedentary), 100-2019 CPM (light activities), 2020-5999 CPM (moderate activities), and above 6000 CPM (vigorous activities) (Troiano et al., 2008) .
Dual-energy X-ray absorptiometry (body composition)
TLBM, lean leg mass, TFM, and leg fat mass were measured by whole body DXA scans using a Hologic Discovery device (Waltham, MA, USA). Lean leg mass and leg fat mass values from the right and left leg were averaged and presented as absolute values (kg). Repeated measurements CV for TLBM, TFM, lean leg mass, and leg fat mass corresponded to 1.4, 1.8, 1.6, and 2.8%, respectively.
Hormone assays
Testosterone levels were measured between 7.30 and 9 AM. Serum TotalT was measured by liquid chromatography tandem mass spectrometry after ether extraction (Statens Serum Institut, Copenhagen, Denmark). The intra-assay CV was less than 10% for total T > 0.2 nmol/L and less than 30% for TotalT in the range between 0.1 and 0.2 nmol/L. SHBG was measured by AutoDELFIA assay. BioT and FreeT were calculated, using http://www.issam.ch/freetesto.htm. A single measurement of testosterone levels was performed to determine eligibility with BioT as a determinant for lowered testosterone (Nielsen et al., 2007; Bhasin et al., 2010; Frederiksen et al., 2012) .
Statistical analyses
Data for each group were checked for normal distribution before analyses, and if absent data were transformed using natural logarithm or analyzed using nonparametric Wilcoxon ranksum test when natural logarithm did not elicit normal distribution. Differences in baseline values were analyzed using unpaired t-test. Outcome measurements were compared between groups using multiple linear regression analysis controlled for baseline values. Coefficients (b) represent the placebo-controlled mean effect of intervention. Results at p < 0.05 were considered statistically significant and are expressed as arithmetic mean AE SD, geometric mean (95% CI), or median (interquartile range) as appropriate. Pearson's correlation analyses were performed to test associations between interventioninduced changes in testosterone levels, muscle mass, muscle mechanical function, and physical function. Statistical analyses were performed with STATA, version 14.
RESULTS
We included 43 patients of which 39 patients completed the trial. TotalT, BioT, FreeT, and SHBG at baseline and after 24-week treatment are displayed in Table 1 . The two intervention groups were comparable at baseline for all measures (Tables 1  and 2 ).
Hormonal levels
As previously reported (Magnussen et al., 2016) , increases (p < 0.05) were observed in TotalT (b = 14.5 nmol/L), BioT (b = 7.6 nmol/L), and FreeT (b = 0.32 nmol/L) during testosterone replacement therapy (TRT) compared with placebo, along with a decrease (p < 0.05) in SHBG (n = À2 nmol/L) ( Table 1) .
Body composition
As previously reported, TLBM increased (b = 1.9 kg) whereas TFM decreased (b = À1.3 kg) during testosterone therapy compared with placebo (Magnussen et al., 2016) . Lean leg mass also increased (b = 0.48 kg) compared with placebo (Table 1 and Fig. 1 ). The increase in TLBM and lean leg mass were not associated with baseline testosterone levels (data not shown). Within the placebo group, lean leg mass decreased after 24 weeks (À0.2 kg, p = 0.01) ( Table 1 and Fig. 1 ). TFM (b = À1.3 kg) and leg fat mass (b = À0.7 kg) decreased during testosterone compared with placebo (Table 1) . Body weight and BMI were unchanged within and between the groups after treatment (Table 1) .
Muscle mechanical function, physical function, and physical activity Knee extension MVC (b = 18.4 Nm, =6.2%), RFD100 (b = 195.0 Nm/s, =24.3%), and Dyn180 (b = 10.2 Nm, =8.2%) increased during TRT compared with placebo ( Fig. 1, Table 2 ). Within the testosterone group, MVC, RFD100, and Dyn180 remained unaffected after treatment. Within the placebo group, RFD100 and Dyn180 decreased after 24-week treatment (p < 0.05) along with a trend in MVC (p = 0.079) ( Table 2) . No changes were observed within or between the two groups after treatment in leg muscle quality evaluated as MVC normalized to lean leg mass (data not shown), leg extension power, normal walking speed, maximum walking speed ( Fig. 1 and Table 2 ), physical activity (Table 2 ), or time spent at different physical activity intensities levels (data not shown).
Correlation analyses
Combined data from the placebo and testosterone group revealed significant correlations between changes in testosterone levels (TotalT or FreeT or BioT) and lean leg mass (r = 0.37-0.39 (range), p < 0.05), along with trends toward significant correlations between changes in testosterone levels (TotalT or FreeT or BioT) and TLBM (r = 0.29-0.03 (range), p = 0.06-0.07 (range)). Moreover, combined data from the placebo and testosterone group revealed significant correlations (p < 0.05)
948 Andrology, 2017, 5, 946-953 between changes in dynamic muscle strength and lean leg mass (r = 0.37, p < 0.05) as well as TLBM (r = 0.39, p < 0.05) and between changes in muscle power and lean leg mass (trend only, r = 0.30, p = 0.07) as well as TLBM (r = 0.37, p < 0.05). Yet, none of these correlations were observed in the placebo and testosterone groups separately. No further correlations were observed.
Adverse events
Adverse events and serious adverse events were recorded throughout the study (Magnussen et al., 2016) . Three patients discontinued in the study due to unrelated illnesses or personal reasons, while one patient in the testosterone group was reduced to 5 g gel once every other day due to elevated hematocrit level. These four patients were excluded from the analyses.
DISCUSSION
The main and novel finding of the present study was the preservation of knee extensor muscle mechanical function and lean leg mass following 24 weeks of testosterone replacement therapy (TRT) compared with placebo in aging men with T2D and lowered BioT.
Muscle mechanical function
As a consequence of the effective TRT, that is, with increases in BioT and FreeT, TRT was shown to counteract the decline in knee extensor muscle mechanical function including isometric strength (MVC), dynamic strength (Dyn180), and explosive strength (RFD100) following the 24-week intervention period. All of these measures have previously been shown to be functionally important, for example, by discriminating older fallers from non-fallers (Pijnappels et al., 2008) . Moreover, the relative percentage changes for MVC, Dyn180, and RFD100 were greater than the repeated measurements CV for each of these parameters. This observation strongly indicates that TRT lead to functionally important changes, specifically by increasing the physiological reserve capacity of muscle mechanical function and thus reducing the risk of reaching a near-future critical low threshold necessary for maintaining physical function. The observation of a decline in knee extensor MVC, RFD100, and Dyn180 during placebo supports the hypothesis that aging men with T2D and lowered BioT levels have an elevated risk of experiencing impairments in muscle mechanical function within a short period of time if no treatment is provided (e.g., the decline in MVC corresponded to À7.0% per year). In comparison, a longitudinal study including 305 older individuals with T2D, but apparently normal range BioT levels reported a decline in knee extensor MVC corresponding to À4.5% per year. While the absence of changes in leg muscle power was surprising, similar findings have been observed in another study after TRT in healthy older men (Storer et al., 2008) and may indicate that leg extensor muscle power (involving contraction velocity and more muscle groups) is differently affected by TRT than knee extensor muscle strength. The latter notion has in fact been shown in isolated single muscle fibers from aging men with lowered testosterone levels (Fitts et al., 2015) .
Interestingly, it appears that an age-threshold exists for the initiation of a rapid decline in muscle mechanical function around 60-70 years of age (Lauretani et al., 2003) . Such a decline plausible starts earlier in men with T2D and lowered testosterone levels (Park et al., 2006) and are linked to other 950 Andrology, 2017, 5, 946-953 mechanisms such as peripheral neuropathy (Morley, 2008) and intermuscular fat infiltration (Delmonico et al., 2009) . Even though physical activity is necessary to preserve good physical function (Morey et al., 2008) , the observed changes in muscle mechanical function were not caused by changes in physical activity levels (assessed by accelerometry) as these remained unaffected in both groups after treatment. Backing this observation, a previous study in aging men (without T2D) also reported no changes in daily physical activity after 12-month TRT (Hildreth et al., 2013) .
The observed preservation of muscle mechanical function was most likely caused by the increase in muscle mass during TRT, in part supported by the correlations shown between changes in leg lean mass and muscle power as well as dynamic muscle strength (combined data from the placebo and testosterone group). In accordance, a large cross-sectional study reported that lower muscle strength with older age was predominantly due to a lower muscle mass (Newman et al., 2003) . Furthermore, factors such as prevention of fat mass gain and intramuscular fat infiltration are also important in terms of maintaining muscle mechanical function and muscle quality in aging persons (Newman et al., 2003; Delmonico et al., 2009) . Although leg fat mass did decrease in our study, leg muscle quality remained unchanged.
In contrast to our findings, two previous RCTs in healthy, slightly older (≥60 years) men did not observe changes in lower leg muscle mechanical function (isometric/dynamic/explosive strength, power) after TRT (Hildreth et al., 2013; Kvorning et al., 2013) . It is possible that the observed preservation of muscle mechanical function during TRT in our study was simply due to the patients being younger than those in the two other studies (Hildreth et al., 2013; Kvorning et al., 2013) . Nevertheless, T2D appears to have a detrimental effect on muscle mechanical function additionally contributing to the changes induced by aging per se. Taken together, TRT may be more efficacious in men with T2D regarding muscle mechanical function compared to men without T2D.
Physical function
The remarkable preservation of muscle mechanical function after TRT in our study did not translate into changes in physical function as evaluated by gait speed. However, the patients included in our study were not yet mobility-limited as reflected by their high gait speed at baseline. There is a nonlinear relationship between leg strength and gait speed, which explains that small changes in physiological capacity may have substantial effects on performance in frail older persons, whereas large changes in capacity have small or no effect in healthy older persons (Buchner et al., 1996) . Thus, a potential improvement in our study could have been undetectable by the applied measurement because of a well-preserved physiological capacity in the patients. These findings are in line with results from previous studies in aging men without T2D (Storer et al., 2008; Hildreth et al., 2013) .
Body composition
This is the first study to report a counteractive effect of TRT compared with placebo on lean leg mass in aging men with T2D and lowered BioT levels. Notable, combined data from the placebo and testosterone group revealed significant correlations between changes in BioT and lean leg mass as well TLBM. Similar increases in lower (Storer et al., 2008; Kvorning et al., 2013) and upper (Hildreth et al., 2013) extremity lean mass were previously demonstrated in RCTs including aging men without T2D (Storer et al., 2008; Hildreth et al., 2013; Kvorning et al., 2013) . While the increase in lean leg mass accounted for approximately 15% of the increase in TLBM in the testosterone group, the decline in lean leg mass accounted for approximately 99% of the decrease in TLBM in the placebo group. Hence, without interventions such as TRT, the lower extremities appear especially susceptible toward muscle atrophy in aging men with T2D and lowered BioT levels. Although the observed decrease in lean leg mass in the placebo group occurred after 24 weeks, this finding is consistent with a longitudinal study (3 years) showing an accelerated loss of muscle mass in aging patients with T2D compared with aging persons without T2D (Park et al., 2006) . If men with T2D have an accelerated loss of muscle mass compared with control persons, these patients might have a higher risk of developing sarcopenia (Volpato et al., 2012; Kalyani et al., 2013) . The latter is likely exacerbated with increasing age, as supported by findings from a previous study showing that baseline TLBM and lean leg mass levels were lower in healthy somewhat older (60-74 years) men, 60.0 and 9.6 kg, respectively, and higher in younger (20-29 years) men, 64.0 and 11.0 kg, respectively (Frost et al., 2015) compared with the patients in the present study.
Strengths and limitations
A major strength of the present study was the study design (double-blinded RCT). Also, the reporting of multiple measures of lower extremity muscle mechanical function (i.e., isometric/ dynamic/explosive strength and power) was a strength as they represent different aspects important for physical function. A limitation was that the study sample size was based on changes in muscle mass, and not on changes of muscle mechanical function measures. Nevertheless, significant changes were observed.
CONCLUSION
In conclusion, we showed that TRT compared with placebo for 24 weeks counteracted a decrease in knee extensor muscle mechanical function, decreased leg fat mass, and increased lean leg mass, whereas physical function was unaffected. Importantly, without TRT, leg lean mass and knee extensor muscle mechanical function deteriorated within 24 weeks in the placebo group in aging men with T2D and lowered BioT levels. TRT may potentially diminish the risk of developing sarcopenia resulting in prolongation of independent living and shortening of rehabilitation periods. Nevertheless, it is still debatable whether TRT is an appropriate counteractive approach to use as the safety of long-term TRT has not yet been clarified, and with the presently conflicting results on cardiovascular risk and mortality (Fernandez-Balsells et al., 2010; Xu et al., 2013) . Therefore, it is still unclear whether the positive effects of TRT on muscle mechanical function and muscle mass outweigh the potential negative effects.
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